Kura Oncology, Inc. and Mirati Therapeutics, Inc. announced a clinical collaboration and supply agreement to evaluate the combination of KO-2806, a next-generation farnesyl transferase inhibitor (FTI), and adagrasib, a highly selective KRASG12C inhibitor, in patients with KRASG12C-mutated non-small cell lung cancer (NSCLC). Under the terms of the agreement, Kura will sponsor the Phase 1 study of KO-2806 and adagrasib in patients with KRASG12C-mutated NSCLC. Mirati will supply Kura with adagrasib for the study.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.06 USD | +2.09% | +10.28% | +39.50% |
Apr. 22 | Sector Update: Health Care Stocks Advance Premarket Monday | MT |
Apr. 22 | Kura Oncology Gets Breakthrough Designation For Leukemia Therapy | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+39.50% | 1.5B | |
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- KURA Stock
- News Kura Oncology, Inc.
- Kura Oncology, Inc. and Mirati Therapeutics, Inc. Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASG12C-Mutated NSCLC